Skip to main content

Table 4 List of currently approved erythropoietin biosimilars

From: What do oncologists need to know about biosimilar products?

Region Active substance (laboratory code) Brand name (pharmaceutical company) Indications in oncology Approval date
Europe Epoetin alfa (HX575) Binocrit (Sandoz) Treatment of anemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumors, malignant lymphoma, or multiple myeloma, and at risk of transfusion as assessed by the patient’s general status (e.g., cardiovascular status, pre-existing anemia at the start of chemotherapy) 28/08/2007
Abseamed (Medice Arzneimittel) 28/08/2007
Epoetin alfa Hexal (Hexal) 28/08/2007
Epoetin zeta (SB309) Retacrit (Hospira) 18/12/2007
Silapo (Stada Arzneimittel) 18/12/2007
Australia Epoetin lambda Aczicrit (Sandoz/Novartis) Treatment of anemia in patients with non-myeloid malignancies where anemia develops as a result of concomitantly administered chemotherapy and where blood transfusion is not considered appropriate 27/01/2010
Grandicrit (Sandoz/Novartis) 27/01/2010
Novicrit (Sandoz/Novartis) 27/01/2010
New Zealand Epoetin alpha (HX575) Binocrit (Novartis) Treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy 27/02/2013